uniQure N.V. (QURE) · Sep 2, 2026 · Other events

uniQure files AMT-130 applications on schedule, leaving four-year data as the next test

BLA and MAA submitted — Q3 2026 submissions completed as previously guided

uniQure reaches its planned U.S. and U.K. filing milestone, but approval still depends on regulators and the coming four-year data.

The filing delivers the milestone investors were already expecting. uniQure had laid out a third-quarter 2026 submission plan, so completing both applications is execution rather than a fresh regulatory surprise. The company announced that it submitted the U.S. BLA and the U.K. MAA. 〔0〕

The regulatory path is open, not secured. The BLA seeks accelerated approval, and uniQure has requested priority review, but neither review acceptance nor approval is established by this filing. 〔1〕 If priority review is granted, the company says the FDA review cycle would be six months after the agency’s 60-day filing review period; that makes this a timing milestone, not an approval event.

The evidence package remains the key vulnerability. The applications rely on the previously announced three-year Phase I/II analysis against a propensity score-matched external control, with no new efficacy magnitude or safety results disclosed here. 〔2〕 The headline claim of slowed disease progression therefore does not materially strengthen the clinical case today.

The next genuine information event is the four-year readout. Management plans to present four-year data before the end of the third quarter. 〔3〕 That update could change how convincing the external-control evidence looks, while the filing itself is best read as a confirmation of the already expected regulatory timetable.

What to watch next

Four-year AMT-130 data, by September 30

Original filing on SEC EDGAR

More uniQure N.V. news

uniQure files AMT-130 applications on schedule, leaving four-year data as the next test | QURE Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.